Insights Advancing the Future of Pharmaceuticals

Equinox Group specializes in assessing the commercial potential of drug programs in all stages of R&D, delivering quantitative insights in disease area strategy, market access, patient share forecasting, patient flow, and epidemiology.

Explore Our Tools
Schedule a Demo
30+ Years of Experience
1,000+ Drug Assessments

Decision Support at Every Stage of the Product Lifecycle

Disease Area Strategy

Find out which indications offer the best commercial opportunities and how to prioritize them

BD & Early R&D

Assess an asset's Clinical Innovation and peak share potential, whether evaluating a BD&L opportunity or developing a TPP

Late-Stage Development

Dive into our patient-share forecasting, patient-flow modeling, and market access tools

Compare All Offerings

The framework at the heart of our analysis and how we use it to predict patient share

The Unmet Need Framework

See the framework in detail →

Recent Articles

Our Insights
Pfizer’s Xtandi + Talzenna Combo Approved in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Scoring a Much Broader Label Than J&J’s Akeega
Oncology
Pfizer’s Xtandi + Talzenna Combo Approved in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Scoring a Much Broader Label Than J&J’s Akeega
Oncology
Read more →
Oncology
Verzenio Has Shown Substantial Efficacy in Liposarcoma
Oncology
Verzenio Has Shown Substantial Efficacy in Liposarcoma
Oncology
Read more →
Oncology
Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC
Oncology
Zegfrovy Has Proven Itself to Be a Viable Alternative to Rybrevant + Chemotherapy in 1L EGFR EXON 20 Insertion-Mutated NSCLC
Oncology
Read more →
Oncology
BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more
Oncology
BMS gains approval for first ever CELMoD, Zenbexus, in relapsed/refractory multiple myeloma and appears poised for the approval of one more
Oncology
Read more →
Oncology
Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge.
Chronic Disease
Cytokinetics’ Myqorzo is On Track For a Significant Label Expansion into nHCM, Where In-Class Rival Camzyos Failed. Payers are the Next Challenge.
Chronic Disease
Read more →
Chronic Disease
Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved
Oncology
Rigel’s Veppanu scores its first nod in HER2-, ER+, ESR1-mutant locally-advanced or metastatic breast cancer, making it the first PROTAC approved
Oncology
Read more →
Oncology
Lipfendra Brings PCSK9i Efficacy with Oral Convenience
Chronic Disease
Lipfendra Brings PCSK9i Efficacy with Oral Convenience
Chronic Disease
Read more →
Chronic Disease
Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care
Oncology
Cogent’s bezuclastinib reduces risk of disease progression or death by 50% in 2L metastatic GIST when combined with standard of care
Oncology
Read more →
Oncology

Want to get in touch?

Click here